Abstract
Portal vein thrombosis (PVT) is a relatively common event in patients with advanced-stage liver cirrhosis, even in patients with a compensated disease. Because of the protean clinical manifestation of PVT, ranging from massive variceal bleeding and mesenteric infarction to the complete absence of any symptom, it is mandatory to provide an early diagnosis and a prompt management. However, even if various treatments have been tested in clinical studies, most of them can be suitable only for a limited number of patients and anticoagulants are recognized as the gold standard, even if the debate about their use in PVT management in cirrhotic patients is still opened. In particular, “old” and “new” generations of anticoagulants have always been used carefully and, sometimes, with skepticism or diffidence in cirrhotic patients. In this review, we report the rationale of anticoagulants use in PVT cirrhotic patients management, analyzing the most accepted controversies and certainties, with a particular attention to their possible role as preemptive therapy.
Keywords: Anticoagulants, liver cirrhosis, portal vein thrombosis, coagulation system, vitamin k antagonists, warfarin, heparin, INR, bleeding, bowel ischemia, recanalization, pro-thormbotic disorders, portal vein thrombosis prevention, factor X inhibitors
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Anticoagulants in Cirrhotic Patients: Controversies and Certainties in PVT Management
Volume: 9 Issue: 3
Author(s): Francesca R. Ponziani, Maria A. Zocco, Annalisa Tortora, Giovanni Gasbarrini and Antonio Gasbarrini
Affiliation:
Keywords: Anticoagulants, liver cirrhosis, portal vein thrombosis, coagulation system, vitamin k antagonists, warfarin, heparin, INR, bleeding, bowel ischemia, recanalization, pro-thormbotic disorders, portal vein thrombosis prevention, factor X inhibitors
Abstract: Portal vein thrombosis (PVT) is a relatively common event in patients with advanced-stage liver cirrhosis, even in patients with a compensated disease. Because of the protean clinical manifestation of PVT, ranging from massive variceal bleeding and mesenteric infarction to the complete absence of any symptom, it is mandatory to provide an early diagnosis and a prompt management. However, even if various treatments have been tested in clinical studies, most of them can be suitable only for a limited number of patients and anticoagulants are recognized as the gold standard, even if the debate about their use in PVT management in cirrhotic patients is still opened. In particular, “old” and “new” generations of anticoagulants have always been used carefully and, sometimes, with skepticism or diffidence in cirrhotic patients. In this review, we report the rationale of anticoagulants use in PVT cirrhotic patients management, analyzing the most accepted controversies and certainties, with a particular attention to their possible role as preemptive therapy.
Export Options
About this article
Cite this article as:
R. Ponziani Francesca, A. Zocco Maria, Tortora Annalisa, Gasbarrini Giovanni and Gasbarrini Antonio, Anticoagulants in Cirrhotic Patients: Controversies and Certainties in PVT Management, Cardiovascular & Hematological Agents in Medicinal Chemistry 2011; 9 (3) . https://dx.doi.org/10.2174/187152511797037448
DOI https://dx.doi.org/10.2174/187152511797037448 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma
Current Medicinal Chemistry Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion
Current Pharmaceutical Design Clinical Profile of Relaxin, a Possible New Drug for Human Use
Current Drug Safety Histological Alterations in the Testicular Tissue Induced by Sildenafil Overdoses
Drug Metabolism Letters Editorial (Thematic Issue: Advances in Particle Engineering and Powder Technology for Pharmaceutical Solid Dosage Forms)
Current Pharmaceutical Design Marine Food Protection in Testicular Damages Caused by Diabetes Mellitus
Current Diabetes Reviews Association of Soluble Adhesion Molecule and C-Reactive Protein Levels with Silent Brain Infarction in Patients with and Without Type 2 Diabetes
Current Neurovascular Research DNA Damage and Epigenetic Changes in Kidney Diseases - Focused on Transcription Factors in Podocytes
Current Hypertension Reviews From Erythropoietin to Its Peptide Derivatives: Smaller but Stronger
Current Protein & Peptide Science Meet Our Editorial Board Member
Current Vascular Pharmacology Early Hematoma Enlargement in Primary Intracerebral Hemorrhage
Current Drug Targets Enhanced Proinflammatory State and Autoimmune Activation: a Breakthrough to Understanding Chronic Diseases
Current Pharmaceutical Design Phosphoinositide 3-Kinase Gamma (PI3Kγ) Inhibitors for the Treatment of Inflammation and Autoimmune Disease
Recent Patents on Inflammation & Allergy Drug Discovery Development of New Drugs that Act Through Membrane Receptors and Involve an Action of Inverse Agonism
Recent Patents on CNS Drug Discovery (Discontinued) Low Testosterone Levels and Metabolic Syndrome in Aging Male
Current Pharmaceutical Design Hemodialysis Membranes for Acute and Chronic Renal Insufficiency
Current Neurovascular Research Gene Therapy with Transcription Factor Decoy Oligonucleotides as a Potential Treatment for Cardiovascular Diseases
Current Drug Targets Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Respiratory Failure in Cancer Patients: Non-Infectious Complications of Antineoplastic Agents for Solid Tumors
Current Respiratory Medicine Reviews Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes
Current Pharmaceutical Design